Antimicrobial resistance (AMR) is one of the main public health challenges worldwide. In the European Union (EU) and European Economic Area (EEA), 33,000 deaths are estimated to be attributed to infections with AMR bacteria annually \[[@r1]\]. Ensuring prudent antimicrobial use is key to an effective response to AMR, as antimicrobial use exerts ecological pressure on bacteria and contributes to the emergence and selection of resistant bacteria. Here, we describe trends in antimicrobial consumption of fluoroquinolones, third-generation cephalosporins and carbapenems between 2001 and 2018 and for AMR in *Escherichia coli* and *Klebsiella pneumoniae*.

Initiatives targeting antimicrobial resistance in EU/EEA
========================================================

The European Antibiotic Awareness Day, a European health initiative and annual event coordinated by the European Centre for Disease Prevention and Control (ECDC), was initiated in 2008 to support EU/EEA countries in their efforts to prevent and control AMR by raising awareness about prudent use of antibiotics \[[@r2]\]. Several EU and global initiatives followed, all prompting action at EU/EEA and at country level. Among these were: (i) a first EU Action Plan against the rising threat from AMR in 2011 \[[@r3]\], (ii) a World Health Organization Global Action Plan on AMR in 2015 \[[@r4]\], (iii) EU Guidelines for the prudent use of antimicrobials in human health \[[@r5]\] (iv) a new European One Health Action Plan against AMR in 2017 \[[@r6]\], and (v) various Council Conclusions adopted by EU Member States between 2008 and 2019 \[[@r7]\]. If successful, these efforts should be reflected in the trends of antimicrobial consumption and of corresponding AMR levels in the EU/EEA.

Analysis of antimicrobial consumption and antimicrobial resistance trends
=========================================================================

To examine trends, we analysed population-weighted EU/EEA-wide data from the European Surveillance of Antimicrobial Consumption Network (ESAC-Net, formerly ESAC) and the European Antimicrobial Resistance Surveillance Network (EARS-Net, formerly EARSS). Using joinpoint version 4.7.0.0 (National Cancer Institute, Bethesda, United States), we performed a regression analysis of data reported to ESAC-Net/ESAC on defined daily doses (DDDs) as listed in the Anatomical Therapeutic Chemical (ATC) Index for 2019 \[[@r8]\] on the consumption of fluoroquinolones (ATC group J01MA), third-generation cephalosporins (ATC group J01DD) and carbapenems (ATC group J01DH) in the community and hospital sector between 2001 and 2018. Using data from EARS-Net/EARSS, corresponding AMR percentages in invasive *E. coli* (2002--18) and *K. pneumoniae* (2006--18) isolates were analysed with the same joinpoint methodology. *E. coli* and *K. pneumoniae* are among the pathogens contributing most to the burden of AMR in the EU/EAA \[[@r1]\] and for which AMR levels have increased substantially during the last decades \[[@r9]-[@r12]\]. Joinpoint regression is a time series analysis technique that is especially useful when the slope of the regression function is expected to change over time, as it allows the analyses to identify the points in time at which trends change and to characterise segments in the time series \[[@r13]\]. Materials and methods are detailed in the [Supplementary Material](/content/10.2807/1560-7917.ES.2019.24.46.1900656#supplementary_data), including an additional sensitivity analysis.

Trends in EU/EEA population-weighted antimicrobial consumption
==============================================================

For antimicrobial consumption, the joinpoint model identified two separate trend segments for third-generation cephalosporin consumption ([Table 1](#t1){ref-type="table"}, [Figure 1](#f1){ref-type="fig"} and three separate trend segments for fluoroquinolone and carbapenem consumption during 2001--2018 ([Table 1](#t1){ref-type="table"}, [Figure 2](#f2){ref-type="fig"} and [Figure 3](#f3){ref-type="fig"}). For the purpose of this article, we use the terms 'increase' or 'decrease' when the trend of the segment was statistically significant (p ≤ 0.05) and we used the term 'stable' when there was no statistically significant trend (p \> 0.05).

###### Joinpoint regression analysis of trends: EU/EEA population-weighted mean consumption expressed in DDD per 1000 inhabitants per day, per antimicrobial group and sector, ESAC-Net/ESAC, 2001--2018

  Segment                                                            Lower endpoint   Upper endpoint   APC                                                      
  ------------------------------------------------------------------ ---------------- ---------------- ------ -------------- -------------- ------------------- ----------------
  **Third-generation cephalosporin consumption (ATC group J01DD)**                                                                                              
  **Community sector**                                                                                                                                          
  All years                                                          2001             NA               2018   NA             **-0.6**       **-1.2 to -0.1**    **0.033**
  Segment 1                                                          2001             NA               2010   2008 to 2013    + 0.7         -0.04 to 1.5        0.062
  Segment 2                                                          2010             2008 to 2013     2018   NA             **-2.1**       **-3.0 to -1.2**      **\< 0.001**
  **Hospital sector**                                                                                                                                           
  All years                                                          2001             NA               2018   NA               **+ 4.3**    **0.8 to 7.8**      **0.015**
  Segment 1                                                          2001             NA               2010   2003 to 2015     **+ 9.0**    **3.8 to 14.5**     **0.002**
  Segment 2                                                          2010             2003 to 2015     2018   NA             -0.9           -6.3 to 4.9         0.746
  **Fluoroquinolone consumption (ATC group J01MA)**                                                                                                             
  **Community sector**                                                                                                                                          
  All years                                                          2001             NA               2018   NA              + 0.1         -0.8 to 1.0         0.780
  Segment 1                                                          2001             NA               2008   2005 to 2013     **+ 2.5**    **1.5 to 3.6**        **\< 0.001**
  Segment 2                                                          2008             2005 to 2013     2016   2012 to 2016   -0.1           -1.2 to 0.9         0.760
  Segment 3                                                          2016             2012 to 2016     2018   NA             **-6.8**       **-12.8 to -0.4**   **0.040**
  **Hospital sector**                                                                                                                                           
  All years                                                          2001             NA               2018   NA              + 2.0         -1.9 to 5.9         0.318
  Segment 1                                                          2001             NA               2003   2003 to 2005     **+ 34.3**   **1.0 to 78.5**     **0.044**
  Segment 2                                                          2003             2003 to 2005     2008   2006 to 2016    + 2.1         -6.2 to 11.2        0.598
  Segment 3                                                          2008             2006 to 2016     2018   NA             **-3.6**       **-5.5 to -1.6**    **0.003**
  **Carbapenem consumption (ATC group J01DH)**                                                                                                                  
  **Hospital sector**                                                                                                                                           
  All years                                                          2001             NA               2018   NA               **+ 9.2**    **3.8 to 14.7**     **0.001**
  Segment 1                                                          2001             NA               2003   2003 to 2012     **+ 46.9**   **4.2 to 107.0**    **0.032**
  Segment 2                                                          2003             2003 to 2012     2013   2006 to 2016     **+ 9.2**    **4.4 to 14.2**     **0.001**
  Segment 3                                                          2013             2006 to 2016     2018   NA             -3.1           -12.4 to 7.2        0.500

APC: annual percentage change; CI: confidence interval; DDD: defined daily doses; ESAC-Net/ESAC: European Surveillance of Antimicrobial Consumption Network/European Surveillance Antimicrobial Consumption project; NA: not applicable.

Statistically significant trends are shown in bold.
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The most recent trend segments, starting between 2008 and 2016 depending on the antimicrobial group and sector, all showed stable or decreasing trends, while segments covering earlier years showed larger variation ([Table 1](#t1){ref-type="table"}, [Figures 1](#f1){ref-type="fig"}-[3](#f3){ref-type="fig"}). For consumption of third-generation cephalosporins in hospital sector ([Table 1](#t1){ref-type="table"}, [Figure 1](#f1){ref-type="fig"}) and carbapenems in the hospital sector ([Table 1](#t1){ref-type="table"}, [Figure 3](#f3){ref-type="fig"}), the most recent segments showed stable levels whereas previous segments showed increasing trends. For consumption of third-generation cephalosporins in the community ([Table 1](#t1){ref-type="table"}, [Figure 1](#f1){ref-type="fig"}) as well as consumption of fluoroquinolones in both sectors ([Table 1](#t1){ref-type="table"}, [Figure 2](#f2){ref-type="fig"}), the most recent segments showed a decreasing trend.

Trends EU/EEA-population weighted antimicrobial resistance percentages
======================================================================

The joinpoint model identified three separate trend segments for *E. coli* ([Table 2](#t2){ref-type="table"}, [Figures 1](#f1){ref-type="fig"}-[2](#f2){ref-type="fig"}), and two trend segments for *K. pneumoniae* ([Table 2](#t2){ref-type="table"}, [Figures 1](#f1){ref-type="fig"}-[3](#f3){ref-type="fig"}). The most recent segments, starting between 2012 and 2013 depending on the microorganism-antimicrobial group combination, showed more favourable trends, i.e. a stable level (fluoroquinolone resistance in *E. coli* and *K. pneumoniae*, third-generation cephalosporin resistance and carbapenem resistance in *K. pneumoniae*) or an increase but with a smaller slope compared with previous segments (third-generation cephalosporin resistance in *E. coli*) ([Table 2](#t2){ref-type="table"}). For almost all microorganism/antimicrobial group combinations, the reduction and/or stabilisation of antimicrobial consumption started before or the same year as the trend in AMR stabilised ([Figures 1](#f1){ref-type="fig"}-[3](#f3){ref-type="fig"}).

###### Joinpoint regression analysis of trends: EU/EEA population-weighted mean percentage of resistance, by microorganism and antimicrobial group, EARS-Net/EARSS, 2002--2018

  Segment                                         Lower endpoint   Upper endpoint   APC                                                     
  ----------------------------------------------- ---------------- ---------------- ------ -------------- -------------- ------------------ ----------------
  ***Escherichia coli***                                                                                                                    
  **Third-generation cephalosporin resistance**                                                                                             
  All years                                       2002             NA               2018   NA               **+ 10.6**   **9.7 to 11.5**      **\< 0.001**
  Segment 1                                       2002             NA               2006   2005 to 2008     **+ 21.8**   **19.0 to 24.7**     **\< 0.001**
  Segment 2                                       2006             2005 to 2008     2012   2011 to 2014     **+ 12.4**   **10.7 to 14.2**     **\< 0.001**
  Segment 3                                       2012             2011 to 2014     2018   NA               **+ 2.0**    **0.8 to 3.2**     **0.004**
  **Fluoroquinolone resistance**                                                                                                            
  All years                                       2002             NA               2018   NA               **+ 4.4**    **3.8 to 5.0**       **\< 0.001**
  Segment 1                                       2002             NA               2006   2005 to 2007     **+ 14.9**   **13.0 to 16.8**     **\< 0.001**
  Segment 2                                       2006             2005 to 2007     2012   2009 to 2015     **+ 2.0**    **1.0 to 3.1**     **0.002**
  Segment 3                                       2012             2009 to 2015     2018   NA              + 0.2         -0.6 to 1.0        0.538
  ***Klebsiella pneumoniae***                                                                                                               
  **Third-generation cephalosporin resistance**                                                                                             
  All years                                       2006             NA               2018   NA               **+ 4.0**    **2.4 to 5.6**       **\< 0.001**
  Segment 1                                       2006             NA               2013   2011 to 2016     **+ 6.7**    **4.6 to 8.8**       **\< 0.001**
  Segment 2                                       2013             2011 to 2016     2018   NA              + 0.4         -2.9 to 3.8        0.809
  **Fluoroquinolone resistance**                                                                                                            
  All years                                       2006             NA               2018   NA               **+ 5.8**    **3.1 to 8.6**     **0.001**
  Segment 1                                       2006             NA               2013   2009 to 2016     **+ 9.6**    **5.7 to 13.6**      **\< 0.001**
  Segment 2                                       2013             2009 to 2016     2018   NA              + 0.8         -4.4 to 6.2        0.748
  **Carbapenem resistance**                                                                                                                 
  All years                                       2006             NA               2018   NA               **+ 19.6**   **10.5 to 29.4**     **\< 0.001**
  Segment 1                                       2006             NA               2013   2010 to 2016     **+ 34.8**   **21.4 to 49.7**     **\< 0.001**
  Segment 2                                       2013             2010 to 2016     2018   NA              + 1.0         -14.7 to 19.7      0.891

APC: annual percentage change; CI: confidence interval; EARS-Net/EARSS: European Antimicrobial Resistance Surveillance Network/European Antimicrobial Resistance Surveillance System; NA: not applicable.

Statistically significant trends are shown in bold.

Discussion
==========

The decreasing or stabilising EU/EEA trends in antimicrobial consumption of fluoroquinolones, third-generation cephalosporins and carbapenems described in this study during the last 6--10 years could be an early signal of the positive effects of antimicrobial stewardship initiatives in EU/EEA countries. Although the ecological study design and different data sources used cannot demonstrate a causal relationship between antimicrobial consumption and AMR, the similar, but less pronounced, stabilising trends or change in slope of AMR percentages are encouraging. Our analysis shows that the increase in AMR in *E. coli* and *K.* *pneumoniae* was most prominent up to 2012/13, after which there is a tendency towards stabilising levels. These trends may be less discernible in shorter time series analyses and underline the usefulness of data retrieved from longer reporting periods.

Our study has several limitations. First, for EARS-Net/EARSS, we could not control for changes in the use of clinical breakpoints over time \[[@r14]\]. However, changes have generally been towards lower breakpoints, which would result in increasing AMR percentages rather than the stabilising trends we report. Second, although there are no indications of major changes in the frequency of blood culture sampling during the study period \[[@r15],[@r16]\], other changes, e.g. in the population under surveillance cannot be excluded and could have influenced the results. For ESAC-Net/ESAC, most countries provided sales data, but a few were only able to provide reimbursement data which do not include antimicrobials dispensed without a prescription or prescribed antimicrobials for which reimbursement was not claimed \[[@r17]\]. Finally, for antimicrobial prescriptions, no information was available on the pathogen and its AMR profile. This could have allowed for identification of the factors and reasons for the observed trends in antimicrobial consumption.

Several other factors than consumption of specific antimicrobial groups may have affected the corresponding AMR trends. The antimicrobial groups included in this study were selected as they are of relevance to treat severe infections caused by *E. coli* and *K. pneumoniae,* but they only contribute to approximately 14% of the total consumption of antibacterials for systemic use (ATC group J01) ([Supplementary Material](/content/10.2807/1560-7917.ES.2019.24.46.1900656#supplementary_data)). Combined resistance to multiple antimicrobial groups increased during our study period, especially for *K. pneumoniae* \[[@r12]\]. Consequently, one antimicrobial agent could also select co-resistant isolates*.* In addition, changes in infection prevention and control (IPC) practices in hospitals and other healthcare settings in EU/EEA countries during the study period could have affected AMR trends, in particular for *K. pneumoniae* for which most infections are healthcare-associated. Longitudinal data on IPC in hospitals in the EU/EEA are not available to analyse such potential impact. Finally, the trends presented here represent the population-weighted mean for the EU/EEA as a whole and individual countries may report different long-term trends and changes, therefore, each EU/EEA country should assess its own situation.

Conclusion
==========

Responding to the increasing public health threat of AMR is a priority in the EU \[[@r3],[@r6],[@r7]\]. The trends of antimicrobial consumption of fluoroquinolones, third-generation cephalosporins and carbapenems and the AMR phenotypes reported here provide an indication that the recent public health efforts promoting prudent antimicrobial use are showing results. Nevertheless, percentages of AMR reported here were comparatively much higher in 2018 than in 2002/06 and trends appear to stabilise or slow down rather than decrease in recent years. The results presented should encourage further efforts aiming to improve antimicrobial stewardship and IPC, which should contribute to reduce AMR in the EU/EEA.
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